Key regions: United Kingdom, Brazil, Europe, France, Canada
The Anti-Fibrinolytic Drugs market in Romania has been experiencing steady growth in recent years.
Customer preferences: Anti-Fibrinolytic drugs are commonly used to treat excessive bleeding. In Romania, the most common use of these drugs is during surgical procedures, particularly in orthopedics and cardiovascular surgeries. The preference for these drugs over other bleeding control methods is due to their effectiveness in preventing blood clots and reducing the need for blood transfusions.
Trends in the market: The Anti-Fibrinolytic Drugs market in Romania has been growing steadily due to an increase in surgical procedures, particularly in the orthopedics and cardiovascular fields. The aging population in Romania has also contributed to the growth of the market, as older individuals are more likely to require surgery and are at a higher risk of excessive bleeding. Additionally, the increasing prevalence of cardiovascular diseases in Romania has led to a higher demand for Anti-Fibrinolytic drugs.
Local special circumstances: Romania has a well-developed healthcare system, with both public and private healthcare facilities available. However, the public healthcare system is often underfunded, leading to long waiting times and a shortage of medical supplies. This has led to an increase in the use of private healthcare facilities, which may have contributed to the growth of the Anti-Fibrinolytic Drugs market in Romania.
Underlying macroeconomic factors: Romania has experienced steady economic growth in recent years, with a growing middle class and an increase in disposable income. This has led to an increase in the demand for healthcare services, including surgical procedures. Additionally, Romania's accession to the European Union has led to an increase in foreign investment and improved access to healthcare technology and supplies, which may have contributed to the growth of the Anti-Fibrinolytic Drugs market.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
